Considering the fact that the MYC transcription factor had a positive effect on IFN-γ-induced PD-L1 expression, combination therapies using PD-1/PD-L1 inhibitors and drugs targeting MYC transcription together with IFN-γ could also be potential treatment strategies for wild-type KRAS and TP53 CRC. Here, KRAS is linked to colorectal carcinoma.